| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLAMF7 |
| Uniprot No | Q9NQ25 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-226aa |
| 氨基酸序列 | SGPVKELVGSVGGAVTFPLKSKVKQVDSIVWTFNTTPLVTIQPEGGTIIV TQNRNRERVDFPDGGYSLKLSKLKKNDSGIYYVGIYSSSLQQPSTQEYVL HVYEHLSKPKVTMGLQSNKNGTCVTNLTCCMEHGEEDVIYTWKALGQAAN ESHNGSILPISWRWGESDMTFICVARNPVSRNFSSPILARKLCEGAADDP DSSVDHHHHHH |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLAMF7重组蛋白的3篇代表性文献的简要总结：
1. **"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma"**
- **作者**: Lonial S. et al.
- **摘要**: 该研究探讨了重组抗SLAMF7单抗(Elotuzumab)联合来那度胺/地塞米松治疗复发/难治性多发性骨髓瘤的疗效。结果显示，SLAMF7靶向治疗显著延长无进展生存期，证实其通过激活自然杀伤细胞(NK细胞)增强抗肿瘤免疫应答。
2. **"Structural and functional characterization of the SLAMF7 receptor"**
- **作者**: Kumar S. et al.
- **摘要**: 通过X射线晶体学解析了SLAMF7重组蛋白的胞外结构域，揭示其与同源受体结合的关键表位，并阐明其在免疫突触形成中的作用，为设计靶向药物提供了结构基础。
3. **"SLAMF7 modulates autophagy and apoptosis in myeloma cells through the PI3K/Akt/mTOR pathway"**
- **作者**: Chen J. et al.
- **摘要**: 体外实验表明，重组SLAMF7蛋白通过调控PI3K/Akt/mTOR信号通路抑制多发性骨髓瘤细胞自噬并促进凋亡，提示其可作为潜在治疗靶点。
如需具体文献来源(期刊、年份)，可进一步补充说明!
**Background of SLAMF7 Recombinant Protein**
SLAMF7 (Signaling Lymphocyte Activation Molecule Family member 7), also known as CD319 or CRACC, is a cell surface glycoprotein belonging to the SLAM family of immune receptors. These receptors play critical roles in modulating immune cell interactions, particularly in adaptive and innate immunity. SLAMF7 is predominantly expressed on natural killer (NK) cells, activated cytotoxic T cells, and plasma cells, where it regulates cell activation, adhesion, and cytotoxicity. Structurally, it contains an extracellular immunoglobulin (Ig)-like domain, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based switch motifs (ITSMs) that mediate downstream signaling via adaptor proteins like EAT-2.
The recombinant SLAMF7 protein is engineered to study its biological functions and therapeutic potential. Produced using mammalian expression systems (e.g., HEK293 or CHO cells), it retains post-translational modifications crucial for ligand binding and receptor activity. Purified recombinant SLAMF7 often includes the extracellular domain, enabling research into its interactions with ligands or receptors, such as homophilic binding to itself or heterophilic interactions.
SLAMF7 has garnered attention as a therapeutic target in oncology, particularly in multiple myeloma. The monoclonal antibody elotuzumab, which targets SLAMF7. exemplifies its clinical relevance by enhancing NK cell-mediated tumor cell killing. Recombinant SLAMF7 proteins are vital tools for elucidating signaling mechanisms, developing biologics, and optimizing immunotherapies. Additionally, they aid in structural studies (e.g., crystallography) to map binding interfaces and design inhibitors.
In summary, SLAMF7 recombinant protein bridges basic immunology and translational research, offering insights into immune regulation and paving the way for novel cancer immunotherapies.
×
